Why I’d snap up the GSK share price for Christmas

I think the GlaxoSmithKline plc (LON: GSK) share price is lagging behind the turnaround in the company’s fortunes.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price had, at the point I checked this morning, moved precisely 0% over the past five years.

But dividends have provided a total yield of 25% as compensation. And as the shares have spent most of the period below their average level, if you’d reinvested the cash in more shares you’d have had a better overall return than that.

I reckon that’s not bad for a period in which Glaxo’s earnings went through a steep dip as it was investing heavily in its drug development pipeline. 

The fruits of that research are coming through, and I don’t think the share price has yet caught up with the progress that’s been made. In its third quarter, Glaxo saw sales of £8.1bn, 3% ahead at actual exchange rates (AER) and 6% ahead at constant exchange rates (CER).

EPS growing

But more importantly, adjusted earnings per share came in 10% ahead at AER and 14% ahead at CER, with cash flow in the first nine months climbing to £2,375m from £1,668m in the same period last year. The figures represent an adjusted operating margin of 31.2%, and I see that as pretty healthy.

Glaxo is still expecting to pay 80p per share in dividends for the full year, the same return it has made for each of the past four years, and that would represent a yield of 5%. It’s around 1.4 times covered by forecast earnings and, ideally, should be covered better than that. But I expect that to come as EPS grows in the next few years, and I see a return to progressive dividends as surely not far off.

Bouncing back

Shire (LSE: SHP) has been through a very erratic period, and though its share price is up nearly 60% over five years, it’s still down from its recent peak in 2015 after a couple of years of big earnings falls — so how lucky you were with the timing pretty much determines how you’ve done recently if you hold the shares.

And there’s been precious little in the way of dividends to compensate shareholders in recent years, with yields coming in around the 0.5% level. So why do I actually like the look of Shire at the moment?

I see it as a potential recovery candidate now, even without the mooted takeover by Takeda Pharmaceutical of Japan. Shire has been recording some notable successes in its pursuit of treatments for rare diseases, and has just got the European nod for its lanadelumab subcutaneous injection, for the treatment of hereditary angioedema. And while a rare disease focus might sound like it wouldn’t result in the same sales volumes as drugs for more common ailments, a specialist could see a lot less competition and higher margins.

Too cheap?

Shire’s P/E has picked up to around the 11 to 12 level, but I can’t help thinking that Takeda’s planned $62bn deal undervalues it. Takeda itself is not having an easy time, with the firm’s founding family against the deal and the debt that it will bring — so much so that Takeda is looking to dispose of up to $10bn in assets and launch an equity issue.

I’d hold off and see how the deal goes, but if it fails I could see an attractive investment falling to a better price here.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »